Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 7/20 | 0.71 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795262 | 1.00 | CTRB1 (0.71) | CTRB1PSMB8PSMB5FOLH1ANPEP | |
| SCHEMBL4315518 | 1.00 | CTRB1 (0.71) | CTRB1PSMB8PSMB5FOLH1ANPEP | |
| SCHEMBL14377905 | 1.00 | CTRB1 (0.71) | CTRB1PSMB8PSMB5FOLH1ANPEP | |
| SCHEMBL3659451 | 0.85 | PSMB5 (0.68) | CTRB1PSMB8PSMB5FOLH1 | |
| SCHEMBL13846042 | 0.85 | PSMB5 (0.68) | CTRB1PSMB8PSMB5FOLH1 | |
| SCHEMBL8751758 | 0.84 | CTRB1 (1.00) | CTRB1PSMB8PSMB5 | |
| SCHEMBL7356960 | 0.84 | CTRB1 (1.00) | CTRB1PSMB8PSMB5 | |
| SCHEMBL10958274 | 0.84 | CTRB1 (1.00) | CTRB1PSMB8PSMB5 | |
| SCHEMBL15075917 | 0.83 | CTRB1 (0.70) | CTRB1PSMB8PSMB5 | |
| SCHEMBL29795284 | 0.83 | CTRB1 (0.70) | CTRB1PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761413-B | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2024-04-12 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| CN-114761413-A | Carbapenem hydrolysis D-type beta-lactamase inhibitor and preparation method thereof | 明知大学校产学协力团 | 2022-07-15 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11058695-B2 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-07-13 | — | — | US | disclosed |
| US-20210137954-A1 | INHIBITOR OF CARBAPENEM-HYDROLYZING CLASS D BETA-LACTAMASES | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-05-13 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040005586-A1 | Novel Artemis/DNA-dependent protein kinase complex and methods of use thereof | NATIONAL INSTITUTES OF HEALTH | 2004-01-08 | — | — | US | disclosed |
| US-6448238-B1 | BORONIC ACIDS USED WITH BETA-LACTAM ANTIBIOTICS, SUCH AS AMOXICILLIN OR CEFTAZIDIME, TO TREAT BETA-LACTAM ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | NORTHWESTERN UNIVERSITY | 2002-09-10 | — | — | US | disclosed |
| US-6417174-B1 | BACTERICIDES | NORTHWESTERN UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
| US-6184363-B1 | Inhibitors of β-lactamases and uses therefor | NORTHWESTERN UNIVERSITY | 2001-02-06 | — | — | US | disclosed |
| EP-1009415-A4 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | UNIV NORTHWESTERN (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1009415-A1 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6075014-A | BACTERICIDES | NORTHWESTERN UNIVERSITY (US) | 2000-06-13 | — | — | US | disclosed |
| WO-1998056392-A1 | INHIBITORS OF β-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058695-B2 | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases | MGAM, LCT, SI | CTRB1 680/4885PSMB8 519/4885PSMB5 512/4885 |
| US-20210137954-A1 | INHIBITOR OF CARBAPENEM-HYDROLYZING CLASS D BETA-LACTAMASES | MGAM, LCT, SI | CTRB1 680/4885PSMB8 519/4885PSMB5 512/4885 |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | LCT, BCHE, GAA | CTRB1 206/4885PSMB8 1057/4885PSMB5 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.